Skip to content

Pulse Biosciences

US · PLSE #2388 by market cap Listed 2016
45.55 +1.14 +2.57%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 20.21 Expensive vs history 81st percentile
5-year average 9.63 · #50 of 51 in Medical Instruments & Supplies
P/E ratio -41.69 Cheap vs history 4th percentile
5-year average -12.95 · forward -36.41
P/S ratio 2,483.14 Expensive vs history 83rd percentile
5-year average -40,504.22 · forward 1,066.04 · #51 of 51 in Medical Instruments & Supplies

Vs. peers Medical Instruments & Supplies

Company Market cap P/E (TTM) P/B Div yield
Pulse Biosciences (PLSE) 3.35B -37.64 18.25 0.00%
Intuitive Surgical (ISRG) 138.33B 48.25 8.65 0.00%
Becton Dickinson & Co (BDX) 57.96B 52.02 2.35 1.97%
Alcon (ALC) 35.92B 54.24 1.64 0.48%
ResMed (RMD) 33.14B 21.46 5.57 1.04%
Medline (MDLN) 32.55B 57.52 2.76 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value48.99 Economic moatNone UncertaintyHigh

Trading 7.5% below Morningstar's fair value estimate.

Fair value

Pulse Biosciences Inc earns a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a minor 3% premium over our quantitative fair value estimate of $48.99 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The firm's valuation metrics decrease our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of 4.7% falls in the bottom 10% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are expensive.

The company's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of -1.8%, for example, sits in the bottom 30% compared with peers globally. The earnings generated by the company relative to its share price is concerning, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Pulse Biosciences discussion 0 comments

Add a comment